2-(3-氟-4-羟基-苯基)-吡喃并[2,3-b]吡啶-4-酮 | 884500-75-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 中文名称: 2-(3-氟-4-羟基-苯基)-吡喃并[2,3-b]吡啶-4-酮
• 英文名称: 2-(3-fluoro-4-hydroxyphenyl)-4H-pyrano[2,3-b]pyridin-4-one
• 英文别名: 2-(3-fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridine-4-one；2-(3-Fluoro-4-hydroxyphenyl)-pyrano[2,3-b]pyridin-4-one；2-(3-fluoro-4-hydroxyphenyl)pyrano[2,3-b]pyridin-4-one
• CAS: 884500-75-8
• 化学式: C₁₄H₈FNO₃
• 分子量: 257.221
• InChiKey: GRZRBMWDXZEEMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  2-甲氧基烟酸甲酯吡啶 在 吡啶盐酸盐 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 4.5h， 生成 2-(3-氟-4-羟基-苯基)-吡喃并[2,3-b]吡啶-4-酮
  参考文献：
  名称：

  TREATMENT OF DISEASES BY EPIGENETIC REGULATION

  摘要：

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防癌症以及败血症，包括NUT中线癌、Burkitt淋巴瘤、急性髓样白血病和多发性骨髓瘤。

  公开号：

  US20130281396A1

文献信息

• Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
  申请人：Wong C.W. Norman

  公开号：US20060205767A1

  公开（公告）日：2006-09-14

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了非自然产生的多酚化合物，其可上调载脂蛋白A-I（ApoA-I）的表达。所公开的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关障碍，例如动脉粥样硬化等。
• Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices
  申请人：Wong Norman C.W.

  公开号：US20090029987A1

  公开（公告）日：2009-01-29

  The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

  本发明涉及一种类似于多酚化合物，可用于抑制哺乳动物中VCAM-1表达、MCP-1表达和/或SMC增殖。所披露的化合物可用于调节炎症状态的标志物，包括血管炎症，并用于治疗和预防炎症和心血管疾病及相关疾病状态。
• FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：Wong Norman C.W.

  公开号：US20090259048A1

  公开（公告）日：2009-10-15

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了一些非自然生成的多酚化合物，它们可以上调载脂蛋白A-I（ApoA-I）的表达。所公开的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关的疾病，如动脉粥样硬化等。
• Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
  申请人：Resverlogix, Inc

  公开号：EP2314295A1

  公开（公告）日：2011-04-27

  The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

  本发明涉及可用于抑制哺乳动物体内 VCAM-1 表达、MCP-1 表达和/或 SMC 增殖的多酚类化合物。所公开的化合物可用于调节炎症状况（包括血管炎症）的标志物，以及治疗和预防炎症和心血管疾病及相关疾病状态。
• Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
  申请人：RESVERLOGIX CORP.

  公开号：EP2332527A2

  公开（公告）日：2011-06-15

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-l (ApoA-l). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了可上调载脂蛋白 A-l（ApoA-l）表达的非天然多酚化合物。所公开的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关疾病，如动脉粥样硬化等。